September24 , 2026

    China grants zero duty to Indian pharma as US blocks imports with 100% tariff

    Related

    India Port Volumes Up 7% in August, Freight Rates Surge 132%

    India’s port cargo volumes increased 7% year-on-year in August,...

    Kerala to Expand Investment Drive, Launch Maritime Projects

    Kerala plans to strengthen its investment promotion efforts and...

    Adani Ports may outperform on volume, profit growth expectations for FY27

    Adani Ports and Special Economic Zone (APSEZ) could see...

    Paradip Port Records 14.82% Rise in Daily Rail Rake Handling

    Paradip Port has recorded a significant improvement in rail...

    MANSA Seeks CBDT Intervention Over PAN, DIN Hurdles in Section 172 Shipping Assessments

    The Maritime Association of Nationwide Shipping Agencies (MANSA) has...

    Share

    In a major development, China has slashed the 30 percent import duty on Indian pharmaceutical products to zero. This landmark step will allow Indian drug manufacturers to export medicines to China without paying any customs duty. Experts say this decision could boost Indian pharma exports by billions of dollars in the coming years.

    Timing important as US raises tariffs

    The announcement comes just after US President Donald Trump imposed a 100 percent tariff on pharma imports, a move that could hurt India’s large drug-exporting industry. With the US market becoming costlier, China’s decision offers Indian companies an alternative market with strong demand for affordable medicines.

    Why it matters for India

    India is known as the ‘pharmacy of the world,’ supplying affordable generic drugs and vaccines across the globe. The Chinese market, with its huge population and growing healthcare needs, has long been difficult for Indian exporters due to high duties. Now, with a zero percent duty, Indian companies will have a level playing field and better access to one of the world’s largest healthcare markets.

    Experts see big opportunity

    Trade analysts believe this move will help balance India-China trade relations, which are often tilted in Beijing’s favour. Pharma industry leaders also expect this change to create thousands of jobs in India, boost revenues, and strengthen India’s position in global healthcare supply chains.